Amarin reported $12.54M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
AbbVie USD 4.34B 56M Jun/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Amarin USD 12.54M 28.57M Jun/2025
AstraZeneca USD 4.96B 127M Jun/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
GlaxoSmithKline GBP 3.18B 45M Jun/2025
Halozyme Therapeutics USD 248.25M 22.74M Sep/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
Novartis USD 5.88B 290M Sep/2025